Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
about
Treatment Individualization in Colorectal CancerStructure of the Human Protein Kinase ZAK in Complex with VemurafenibTargeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaSystems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation CycleA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerParadoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cellsMolecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.Comprehensive pharmacological profiling of neurofibromatosis cell lines.Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.Modeling anaplastic thyroid carcinoma in the mouse.Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.Molecular profiling of gliomas: potential therapeutic implications.Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine.BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management.Rho GTPases: Anti- or pro-neoplastic targets?Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Drug-induced eruptive melanocytic nevi.NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A targeting and MAPK cascade activation.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.A three-drug combination to treat BRAF-mutant cancers.PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.New perspectives for targeting RAF kinase in human cancer.MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.Molecular Insights and Functional Implication of LRRK2 Dimerization.Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway.Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine.Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
P2860
Q26776215-0F2C2FFF-7990-43CD-B131-DED5288E5AE6Q27704282-6C32DD8C-C795-4035-B60F-F8BDB1D6A1C1Q27853209-C252106B-FF11-4B52-A272-C5AB85C757FBQ28548486-B10A69D0-E74E-4B84-B6E2-4E954BDDEAE2Q28554490-6CA0FCE2-5BD1-4F20-AB28-5FABF918E63BQ28817145-1CFEECD6-65B4-402B-8E1E-F66C06B113BBQ28833514-DD003BBC-7B21-40F7-89C1-D97535DC176AQ30391310-5509C672-7F6D-4D1B-BEDB-D8E3A9C5FD2FQ30395364-AB60D622-F50C-43B2-AE15-69C89F236DE1Q33622690-1E60720C-47BC-4B04-A502-2748B26AD506Q35752069-32FA2008-8EF0-4ABE-AC3F-B2FE6BB491E4Q35754265-CA56EEB0-93EB-4C80-B45F-12A1FD6FB5F4Q38270915-1AF78CB7-6917-4CEB-A3AB-95384753E68FQ38370667-464C3463-A33B-49AB-BF29-4DC92548629FQ38539422-43935F68-9653-4A2E-8D31-1905700BD875Q38634557-57BB5721-1401-4310-9D63-CB974696F7BDQ38742012-62D31FF6-0DEF-4E14-8F4D-D281327C14C2Q38764961-19FF3E6A-14CE-435F-84E0-54B5750DB6A1Q38780866-6BE8D941-1022-44AE-843A-89B9B5E931DEQ38813996-ED3F98B6-0A6D-47DF-9CB9-24E67092708DQ38985224-8744061B-ED0F-4605-B133-D2235C4D5E57Q39400435-20234C7B-E08C-40C2-A32D-FFC37B68C825Q39734806-07DD9DEB-EFED-4B8F-921E-1064E8BA90FCQ40579796-5143158C-4368-4A6A-8E3A-69383D9B09C2Q41694346-D072A044-6B66-4C23-A9EC-EBE1D97C37B9Q44502910-73DBCEEC-9E4C-4AE9-9EB7-BCCBCDDBBA4CQ46172410-C87510BF-9F17-4940-94BD-6ABB173ED957Q47142625-A31CC089-5C81-46E0-BE53-B2394D084C92Q47688064-5FC8796B-215B-4EE8-B3DD-2A6F7992BA6BQ51023212-846F8341-7723-4647-B930-72C237FDB952Q51082151-D15615C4-B6A1-4BCA-AC61-6C3D45D03308Q52936751-155DDD51-46AC-4855-8DF3-CC9EEB7DF1BEQ54115748-0C94E99D-49A6-41C4-9401-D9691336A013Q54976914-01A71531-655B-4D2D-825B-B78259D9397FQ54976942-6AD5EE80-6B58-4D9C-8153-009C3A135994Q58699001-A9E433C9-6751-41F9-9B5C-0942DF4383B3
P2860
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
@en
type
label
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
@en
prefLabel
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
@en
P2093
P2860
P921
P356
P1476
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors
@en
P2093
D D Stuart
M Holderfield
P2860
P2888
P304
P356
10.1038/BJC.2014.139
P407
P5008
P577
2014-03-18T00:00:00Z
2014-08-12T00:00:00Z
P5875
P6179
1043663778